ID   OX-CO-2 R2 Cetux
AC   CVCL_A2CI
SY   OXCO-2 R2 Cetux
DR   Cosmic; 2841377
DR   Wikidata; Q105510526
RX   PubMed=25623215;
CC   Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Ile491Met (c.1473A>G); ClinVar=VCV001404733; Zygosity=Heterozygous; Note=Acquired during resistance selection process (PubMed=25623215).
DI   NCIt; C4910; Colon carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2H53 ! OX-CO-2
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 6
//
RX   PubMed=25623215; DOI=10.1158/1078-0432.CCR-14-2821;
RA   Arena S., Bellosillo B., Siravegna G., Martinez A., Canadas I.,
RA   Lazzari L., Ferruz N., Russo M., Misale S., Gonzalez I., Iglesias M.,
RA   Gavilan E., Corti G., Hobor S., Crisafulli G., Salido M., Sanchez J.,
RA   Dalmases A., Bellmunt J., De Fabritiis G., Rovira A.,
RA   Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.;
RT   "Emergence of multiple EGFR extracellular mutations during cetuximab
RT   treatment in colorectal cancer.";
RL   Clin. Cancer Res. 21:2157-2166(2015).
//